Skip to main content
. Author manuscript; available in PMC: 2012 Oct 29.
Published in final edited form as: Eur Urol. 2011 Jun 22;61(2):363–369. doi: 10.1016/j.eururo.2011.06.034

Fig. 2.

Fig. 2

Overall survival (a) from day 1 of cycle 10 and beyond day 90 for those with and without ≥30% prostate-specific antigen (PSA) decline by day 90, (b) for those with and without PSA decline from cycle 9 to cycle 10, and (c) for those with and without ≥30% PSA decline by day 90.